Prednisolone-containing liposomes accumulate in human atherosclerotic macrophages upon intravenous administration. - Wikidata - wikimedia - TriplyDB

Prednisolone-containing liposomes accumulate in human atherosclerotic macrophages upon intravenous administration.

Prednisolone-containing liposomes accumulate in human atherosclerotic macrophages upon intravenous administration.

http://www.wikidata.org/entity/Q36223678

about

Nanoparticles for Cardiovascular Imaging and Therapeutic Delivery, Part 2: Radiolabeled Probes Liposomal prednisolone inhibits vascular inflammation and enhances venous outward remodeling in a murine arteriovenous fistula model.Nanotechnology in diagnosis and treatment of coronary artery disease.Thresholds for Arterial Wall Inflammation Quantified by (18)F-FDG PET Imaging: Implications for Vascular Interventional Studies Novel Drug Delivery Systems Tailored for Improved Administration of Glucocorticoids.Boosting Inflammation Resolution in Atherosclerosis: The Next Frontier for Therapy.Detection and treatment of atherosclerosis using nanoparticles.Recent Advances in Managing Atherosclerosis via Nanomedicine.Local delivery of liposomal prednisolone leads to an anti-inflammatory profile in renal ischaemia-reperfusion injury in the rat.Nanomedicine for immunosuppressive therapy: achievements in pre-clinical and clinical research.Liposomal nano-drugs based on amphipathic weak acid steroid prodrugs for treatment of inflammatory diseases.Resident and Monocyte-Derived Macrophages in Cardiovascular Disease.Liposome-based immunotherapy against autoimmune diseases: therapeutic effect on multiple sclerosis.The European project NanoAthero to fight cardiovascular diseases using nanotechnologies.Combating atherosclerosis with targeted nanomedicines: recent advances and future prospective.Synthesis and drug release profile of a dual-responsive poly(ethylene glycol) hydrogel nanocomposite

P2860

Q26796221-D43BA13E-5669-43AA-8101-46AF3B1BB495 Q27322891-D45D5F73-DC5F-453C-B857-0C06C7E0B168 Q30362371-228E36B0-50B3-4665-AC9D-9A947D4831D3 Q37324445-0FAE2A1F-94EA-4702-A43E-B07E75E59C41 Q38637805-8C9ED255-7826-4B42-9474-F35FBBA9724F Q38681468-8F4694BC-D64D-4EF2-8E02-14EC98323661 Q38848673-BB0F472E-B0A5-42D9-9C26-A21F1E52AD55 Q47251361-87B0A5EA-5C7A-4B96-958C-14B867FE2ECA Q47677126-18A39158-FE7A-4522-A586-E5C4493D9C0F Q47771876-BF59CB91-AC18-47F6-9A8B-30FDFAF90733 Q47975293-26CF64C4-0EBA-45B2-8918-72672DF9532F Q50187351-F29F3CDF-B06D-4A92-969E-FC6D3859EED1 Q50953987-4DAC3E09-B2B9-46B8-BAC5-24AC635A032C Q51639424-E64DE942-57A6-449C-B8B4-70A1B3D9FCAF Q55035936-5AB55CC5-DB20-4959-A3F7-7F74DF544D5F Q57377430-A44841B9-5BCB-4BE4-8F65-0BE3BF61688F

P2860

Prednisolone-containing liposomes accumulate in human atherosclerotic macrophages upon intravenous administration.

http://www.wikidata.org/entity/Q36223678

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Prednisolone-containing liposo ...... on intravenous administration.

@ast

Prednisolone-containing liposo ...... on intravenous administration.

@en

type

label

Prednisolone-containing liposo ...... on intravenous administration.

@ast

Prednisolone-containing liposo ...... on intravenous administration.

@en

prefLabel

Prednisolone-containing liposo ...... on intravenous administration.

@ast

Prednisolone-containing liposo ...... on intravenous administration.

@en

P1433

Q36223678-F0BDEA26-B644-4CD0-96A1-1B2192443C17

P1476

Q36223678-8004D22D-FF93-4E80-8726-98C27C2E6605

P2093

Q36223678-1206EBCE-92E6-415A-86F8-744751ED102D

Q36223678-156536E8-5D58-49BA-A153-E1442A495DAF

Q36223678-2D401AB6-C98A-481B-A055-A01CDF7A028C

Q36223678-41D07BBB-DCDE-4110-8563-577A9CA53FDA

Q36223678-47FF6640-844B-4E05-97AB-B2DFBB7C33D7

Q36223678-4CF5AA22-67B6-4CF6-A798-C8DFF28D9C61

Q36223678-64C10288-A980-4CF4-90C2-4567B4E2FBB2

Q36223678-68A7FEDE-D66A-474E-BB3E-1CE737F044FD

Q36223678-7490DA28-1788-4D03-8143-404424CAB468

Q36223678-7BAF48F3-0EA8-4E1F-B7F0-C238C1892404

P2860

Q36223678-01AFDEA6-7FC9-4275-BDF5-29EB8265BA76

Q36223678-0864237A-ECF4-429C-BD05-EE4901502BB2

Q36223678-0BE5F850-4365-465B-96CD-F2421A389790

Q36223678-188FAC29-36FD-4C13-B76A-BF5C254B0E9C

Q36223678-1BB0A2A0-0B6E-4164-9003-B06F8367B7F7

Q36223678-2099B017-7511-4F64-8BE8-87A38AE5D28F

Q36223678-28E7A911-770A-43B0-AA40-5153E035E715

Q36223678-30566B3E-538C-469D-9013-AD202D90042C

Q36223678-3CA42583-FC58-414C-B294-BF301A6D6C40

Q36223678-41E53073-79F0-4C30-99EF-D4A775B0C719

P304

Q36223678-156BE6B0-5EC1-415E-AC1C-C8CEAA88D004

P31

Q36223678-A3C6A8A1-E6E1-482F-8BEF-1B8C5C144B6D

P356

Q36223678-AD242442-78AB-472E-83CF-1AD8B1E7402E

P433

Q36223678-38F122CD-7FBD-41B7-BACC-794B28B35AF8

P478

Q36223678-2102A036-7E29-4F06-9890-62ED7A5B6A5A

P50

Q36223678-D85154BD-010B-4CAA-9D7C-FB80D81ED687

Q36223678-D8E5B089-0434-42AE-BC35-F1DA44B1F325

Q36223678-DE09DCE9-F898-4716-8DD3-64BB9A78543B

P577

Q36223678-49F1BC27-FCB3-40CD-9283-FD160A655136

P698

Q36223678-78A2969B-25A8-42EF-8224-CF26FCD0FBAE

P921

Q36223678-0E57D95F-D250-4380-9CBB-BB727FC4C3D9

P932

Q36223678-0B81BD62-28A0-41B5-96F5-B8C441E4D333

P356

J.NANO.2015.02.021

P1433

Nanomedicine: Nanotechnology, Biology and Medicine

P1476

Prednisolone-containing liposo ...... on intravenous administration.

@en

P2093

Aart J Nederveen

http://www.w3.org/2001/XMLSchema#string

Claudia Calcagno

http://www.w3.org/2001/XMLSchema#string

Diederik F van Wijk

http://www.w3.org/2001/XMLSchema#string

Dink A Legemate

http://www.w3.org/2001/XMLSchema#string

Dominik M Schulte

http://www.w3.org/2001/XMLSchema#string

Erik S Stroes

http://www.w3.org/2001/XMLSchema#string

Fleur M van der Valk

http://www.w3.org/2001/XMLSchema#string

Gert Storm

http://www.w3.org/2001/XMLSchema#string

Hein J Verberne

http://www.w3.org/2001/XMLSchema#string

Josbert M Metselaar

http://www.w3.org/2001/XMLSchema#string

P2860

Regulated accumulation of desmosterol integrates macrophage lipid metabolism and inflammatory responses

Modulation of 11β-hydroxysteroid dehydrogenase as a strategy to reduce vascular inflammation

Imaging and nanomedicine in inflammatory atherosclerosis

The emerging nanomedicine landscape

Recent advances with liposomes as pharmaceutical carriers

Dose translation from animal to human studies revisited

Drug delivery systems: entering the mainstream

Progress and challenges in translating the biology of atherosclerosis

Apolipoprotein A-I, cyclodextrins and liposomes as potential drugs for the reversal of atherosclerosis. A review.

Perspectives and opportunities for nanomedicine in the management of atherosclerosis.

P304

1039-1046

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.NANO.2015.02.021

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Willem J.M. Mulder

Geesje M Dallinga-Thie

P577

2015-03-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25791806

http://www.w3.org/2001/XMLSchema#string

P921

atherosclerosis

P932

4625798

http://www.w3.org/2001/XMLSchema#string